Pralsetinib was granted accelerated approval by the FDA in 2020 for adults with metastatic RET fusion-positive NSCLC, and patients with metastatic RET-mutant MTC that may or may not be radioactive iodine-refractory (275). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.